Submission of US NDA for ORPATHYS® plus TAGRISSO

Summary by AI BETAClose X

HUTCHMED announced that AstraZeneca has submitted a New Drug Application to the US FDA for ORPATHYS plus TAGRISSO for treating MET-driven EGFR-mutated non-small cell lung cancer that has progressed after EGFR-TKI therapy. This submission is supported by the global SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free and overall survival compared to chemotherapy, with a safety profile consistent with known data. This combination offers a potential biomarker-directed, all-oral treatment option for patients with a significant unmet need.

Disclaimer*

UK 100

Latest directors dealings